ONCAlert | Upfront Therapy for mRCC

GI Cancers VIEW MORE >>

TT-00420, an investigational spectrum-selective multiple kinase inhibitor received an orphan drug designation from the FDA for the treatment of cholangiocarcinoma, TransThera Biosciences Co. Ltd announced in a press release.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.